Xeris Biopharma Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
7analysts covering
FY Revenue (est.)
$387.5Mnext fiscal year
FY EPS (est.)
-$0.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| XP-8121 Program Review | 1 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly83.1MTarget: 380000000 to 390000000
Recorlev Net Product Revenue Quarterly49.8MTarget: 1000000000 by 2035
Gvoke Net Product Revenue Quarterly20.8MTarget: Modest growth navigating Medicare headwinds
Keveyis Net Product Revenue Quarterly11.9MTarget: Stable long-term contribution protected by patent
Watch Items
- XP-8121 Phase 3 Trial InitiationTrigger: Late 2026 (expected September - December 2026)Action: Monitor R&D expense increases (guided up by ~$25M in 2026) and patient enrollment milestones.
- Recorlev Patent Infringement Litigation (Hatch-Waxman Act)Trigger: Ongoing litigation in U.S. District Court for the District of New Jersey against Torrent and SomersetAction: Track legal developments, court rulings, and potential generic entry threats before March 2040 patent expiration.
- Gvoke Medicare Channel HeadwindsTrigger: Flat year-over-year revenue growth in Q1 2026 due to Medicare out-of-pocket dynamicsAction: Evaluate commercial strategy adjustments and formulary positioning to restore growth.
Research as of 19 Jun 2026